{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:47:23Z","timestamp":1762674443898,"version":"3.41.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>We examined the association between androgen deprivation therapy (ADT) use and the risk of mild cognitive impairment (MCI) among prostate cancer patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We included 241 cognitively unimpaired men, aged 70 to 90, with a history of prostate cancer before enrollment in the population-based Mayo Clinic Study of Aging. Using the Rochester Epidemiology Project medical records-linkage system, ADT use and length of exposure were abstracted. Follow-up visits occurred every 15 months and MCI diagnoses were made based on clinical consensus. Cox proportional hazards models, with age as the timescale, were used to examine the association between ADT use (yes\/no) and length of exposure with the risk of MCI adjusting for education, apolipoprotein E, depression, and the Charlson Index score.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>There was no association between any ADT use (27.8% of participants) and the risk of MCI in the multivariable model [hazard ratio (HR), 1.25; 95% confidence interval (CI), 0.75-2.10]. Although not significant, there was an ADT dose-response relationship for risk of MCI: &lt;5 years versus no use (HR, 1.08; 95% CI, 0.60-1.96) and \u22655 years versus not use (HR, 1.89; 95% CI, 0.83-4.27).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>ADT use among prostate cancer patients was not associated with an increased risk of developing MCI.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/wad.0000000000000415","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T06:03:46Z","timestamp":1600754626000},"page":"44-47","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Androgen Deprivation Therapy Use and Risk of Mild Cognitive Impairment in Prostate Cancer Patients"],"prefix":"10.1097","volume":"35","author":[{"given":"Hector","family":"Alonso-Qui\u00f1ones","sequence":"first","affiliation":[{"name":"School of Medicine, University of Puerto Rico, San Juan, Puerto Rico"},{"name":"Mayo Clinic Alix School of Medicine and Center for Clinical and Translational Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley J.","family":"Stish","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremiah A.","family":"Aakre","sequence":"additional","affiliation":[{"name":"Health Sciences Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clinton E.","family":"Hagen","sequence":"additional","affiliation":[{"name":"Health Sciences Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald C.","family":"Petersen","sequence":"additional","affiliation":[{"name":"Health Sciences Research"},{"name":"Neurology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"Mielke","sequence":"additional","affiliation":[{"name":"Health Sciences Research"},{"name":"Neurology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/cncr.20955","article-title":"Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma","volume":"103","author":"Shahinian","year":"2005","journal-title":"Cancer"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"key":"R5-20250527","first-page":"303","article-title":"Complications of androgen deprivation therapy: prevention and treatment","volume":"18","author":"Holzbeierlein","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1634\/theoncologist.8-5-474","article-title":"Andropause: symptom management for prostate cancer patients treated with hormonal ablation","volume":"8","author":"Thompson","year":"2003","journal-title":"Oncologist"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1200\/JCO.2014.60.1963","article-title":"Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison","volume":"33","author":"Gonzalez","year":"2015","journal-title":"J Clin Oncol"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00520-014-2285-1","article-title":"Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis","volume":"22","author":"McGinty","year":"2014","journal-title":"Support Care Cancer"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/ADR-180052","article-title":"No relationship of anti-androgens to Alzheimer\u2019s disease or cognitive disorder in the MedWatch Database","volume":"2","author":"Lehrer","year":"2018","journal-title":"J Alzheimers Dis Rep"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/cncr.30320","article-title":"Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer","volume":"123","author":"Alibhai","year":"2017","journal-title":"Cancer"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1046\/j.1471-4159.2003.02114.x","article-title":"Androgens modulate beta-amyloid levels in male rat brain","volume":"87","author":"Ramsden","year":"2003","journal-title":"J Neurochem"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.yhbeh.2015.05.020","article-title":"The impact of luteinizing hormone and testosterone on beta amyloid (Abeta) accumulation: animal and human clinical studies","volume":"76","author":"Verdile","year":"2015","journal-title":"Horm Behav"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1017\/S1478951507000442","article-title":"Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions","volume":"5","author":"Nelson","year":"2007","journal-title":"Palliat Support Care"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"e196562","DOI":"10.1001\/jamanetworkopen.2019.6562","article-title":"Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer","volume":"2","author":"Jayadevappa","year":"2019","journal-title":"JAMA Netw Open"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000115751","article-title":"The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics","volume":"30","author":"Roberts","year":"2008","journal-title":"Neuroepidemiology"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/archneur.1991.00530190071018","article-title":"The short test of mental status. Correlations with standardized psychometric testing","volume":"48","author":"Kokmen","year":"1991","journal-title":"Arch Neurol"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13854049208401877","article-title":"Mayo\u2019s older Americans normative studies: WAIS-R norms for ages 56 to 97","volume":"6","author":"Ivnik","year":"1992","journal-title":"Clin Neuropsychol"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","article-title":"Mild cognitive impairment as a diagnostic entity","volume":"256","author":"Petersen","year":"2004","journal-title":"J Intern Med"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","article-title":"An inventory for measuring clinical anxiety: psychometric properties","volume":"56","author":"Beck","year":"1988","journal-title":"J Consult Clin Psychol"},{"key":"R23-20250527","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.juro.2017.11.136","article-title":"Cognitive impairment in men with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis","volume":"199","author":"Sun","year":"2018","journal-title":"J Urol"},{"key":"R24-20250527","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cncr.23658","article-title":"Cognitive effects of hormone therapy in men with prostate cancer: a review","volume":"113","author":"Nelson","year":"2008","journal-title":"Cancer"}],"container-title":["Alzheimer Disease &amp; Associated Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WAD.0000000000000415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T19:04:34Z","timestamp":1748372674000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/WAD.0000000000000415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/wad.0000000000000415","relation":{},"ISSN":["0893-0341"],"issn-type":[{"type":"print","value":"0893-0341"}],"subject":[],"published":{"date-parts":[[2020,10,1]]},"assertion":[{"value":"2020-06-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}